Nuveen
ACRS icon

Nuveen’s Aclaris Therapeutics ACRS Stock Holding History

Nuveen’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.47M Buy
278,404
+160,384
+136% +$715K ﹤0.01% 2739
2026
Q1 		$443K Sell
118,020
-119,810
-50% -$404K ﹤0.01% 2890
2025
Q4 		$716K Hold
237,830
– – ﹤0.01% 2751
2025
Q3 		$452K Hold
237,830
– – ﹤0.01% 2934
2025
Q2 		$338K Buy
+237,830
New +$322K ﹤0.01% 3004
2024
Q2 		– Sell
-166,656
Closed -$207K – 3330
2024
Q1 		$207K Sell
166,656
-273,245
-62% -$326K ﹤0.01% 3177
2023
Q4 		$462K Sell
439,901
-20,412
-4% -$62.3K ﹤0.01% 3032
2023
Q3 		$3.15M Buy
460,313
+258,896
+129% +$2.21M ﹤0.01% 2099
2023
Q2 		$2.09M Buy
201,417
+12,156
+6% +$110K ﹤0.01% 2327
2023
Q1 		$1.53M Sell
189,261
-12,336
-6% -$157K ﹤0.01% 2442
2022
Q4 		$3.17M Sell
201,597
-19,827
-9% -$319K ﹤0.01% 2167
2022
Q3 		$3.48M Sell
221,424
-29,290
-12% -$461K ﹤0.01% 2106
2022
Q2 		$3.5M Sell
250,714
-66,826
-21% -$936K ﹤0.01% 2158
2022
Q1 		$5.12M Buy
317,540
+15,384
+5% +$210K ﹤0.01% 2048
2021
Q4 		$4.39M Buy
302,156
+30,066
+11% +$456K ﹤0.01% 2194
2021
Q3 		$4.94M Buy
272,090
+88,303
+48% +$1.42M ﹤0.01% 2215
2021
Q2 		$3.23M Buy
+183,787
New +$4.17M ﹤0.01% 2477
2020
Q2 		– Sell
-110,000
Closed -$115K – 3269
2020
Q1 		$115K Buy
110,000
+8,849
+9% +$12K ﹤0.01% 3053
2019
Q4 		$191K Sell
101,151
-14,287
-12% -$23.7K ﹤0.01% 3081
2019
Q3 		$125K Sell
115,438
-12,522
-10% -$17.8K ﹤0.01% 3153
2019
Q2 		$280K Buy
+127,960
New +$697K ﹤0.01% 3125

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Nuveen's ACRS Position: Q2 2026 in Review

Nuveen increased its Aclaris Therapeutics (ACRS) stake by 136% in Q2 2026, buying an estimated $715K and bringing the position to 278,404 shares worth $1.47M. The position accounts for ﹤0.01% of the portfolio, ranked #2739.

Nuveen first reported a position in ACRS in Q2 2019 and has held it in 21 quarters since. The position peaked at $5.12M in Q1 2022. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Nuveen held 278,404 shares of Aclaris Therapeutics worth $1.47M as of Q2 2026.
  • Nuveen bought 160,384 Aclaris Therapeutics shares in Q2 2026, an estimated $715K.
  • Aclaris Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2739 holding.
  • Nuveen first reported a position in Aclaris Therapeutics in Q2 2019 and has held it in 21 quarters since.
  • Nuveen's Aclaris Therapeutics position peaked at $5.12M in Q1 2022.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.